Search results
Biogen to acquire HI-Bio for up to $1.8 billion By Investing.com
Investing.com· 3 days agos portfolio in immunology and rare diseases. HI-Bio's lead asset, felzartamab, is an anti-CD38...
Biogen to acquire privately held Human Immunology Biosciences for $1.15 billion upfront
Market Watch· 4 days agoThe drug has received Breakthrough Therapy Designation and Orphan Drug Designation from the U.S ...
Biogen is buying up an immune drug developer for $1.8 billion
Quartz· 4 days agoBiotechnology giant Biogen said on Wednesday that it is acquiring immune drug developer Human...
Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline
Zacks via Yahoo Finance· 3 days agoHI-Bio has plans to advance felzartamab into phase III for all indications. HI-Bio has received...
Biogen enters deal to acquire HI-Bio for $1.8bn
Pharmaceutical Technology via Yahoo Finance· 3 days agoThe US Food and Drug Administration previously awarded breakthrough therapy and orphan drug (ODD) designations ...
GC Biopharma/Novel Pharma's Sanfilippo Syndrome Treatment Obtains FDA IND Clearance
FOX 5 San Diego· 5 days agoKS) and Novel Pharma have announced that the U.S. FDA has cleared the investigational new drug (IND) application for their jointly developed MPSIIIA (Sanfilippo Syndrome Type ...
Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual...
FOX 59 Indianapolis· 2 days agoMabwell (688062.SH), an innovation-driven biopharmaceutical company, announced the data and latest...
NLS Pharmaceutics Announces Receipt of Additional Staff Delisting Determination from Nasdaq
Morningstar· 1 day agoZÜRICH, SWITZERLAND / ACCESSWIRE / May 24, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the ...
Calliditas Therapeutics stock target lifted on strong sales By Investing.com
Investing.com· 2 days agoOn Thursday, Jefferies, a global investment banking firm, raised the stock price target for...
Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human...
Morningstar· 4 days agoBiogen Inc. (Nasdaq: BIIB) and Human Immunology Biosciences (HI-Bio™), a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated ...